Cervical Adenosquamous Cell Carcinoma, Cervical Squamous Cell Carcinoma in Situ, Neoplasms, Stage IB Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer
Conditions
Keywords
Cervical Cancer, Radiation Therapy, Chemotherapy, Nimotuzumab, Cisplatin
Brief summary
The purpose of this phase II trial is to determine the feasibility and efficacy of nimotuzumab combined with concurrent chemoradiotherapy for initially inoperable locally advanced cervical squamous cell carcinoma.
Detailed description
This phase II trial is studying how well giving nimotuzumab together with radiation therapy and cisplatin works in treating patients with previously untreated locally advanced cervical cancer. Monoclonal antibodies, such as nimotuzumab, a humanized anti-epidermal growth factor receptor (EGFR) monoclonal antibody that is approved in many countries for the treatment of EGFR-positive cancers. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Nimotuzumab also stop the growth of cervical cancer by increasing the effect of chemotherapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving nimotuzumab together with radiation therapy and cisplatin may kill more tumor cells.
Interventions
DRUGNimotuzumab
Patients receive nimotuzumab IV over 90 minutes on days 1, 8, 15, 22, 29, 36,43.
DRUGCisplatin
Patients undergo cisplatin, 25-40 mg/m2 a week for 4 or 5weeks
RADIATIONexternal-beam radiation
Patients undergo pelvic EBRT once daily, 5 days a week, for 5 weeks for a total of 45-50.4Gy
RADIATIONbrachytherapy
high-dose rate brachytherapy,6Gy once weekly,for a total of 24-30Gy
Sponsors
Zhujiang Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* All volunteers will sign the informed consent. * Histologically confirmed squamous cell of the uterine cervix, EGFR(+). * The FIGO stage (IIB-IVA) and was not available for surgical treatment. * There is at least one tumor lesion that is measurable by RECIST. * During the study, contraception should be ensured. * Karnofsky performance status \>60. * WBC \>= 3,000/mm\^3 * Absolute granulocyte count \>= 1,500/mm\^3 * Platelet count \>= 100,000/mm\^3 * INR \< 1.5 * Total bilirubin =\< 1.5 mg/dL * Serum creatinine =\< 1.5 mg/dL * AST and ALT =\< 2.5 times upper limit of normal (ULN) * Serum calcium =\< 1.3 times ULN * Hemoglobin \>= 9g/dL (transfusion allowed)
Exclusion criteria
* Positive para-aortic lymph nodes or positive lymph nodes beyond pelvic * Prior invasive malignancy (except nonmelanomatous skin cancer) * Contraindication of chemotherapy; * Rare pathological subtype; * Cervical cancer patients underwent hysterectomy, laparoscopic surgery or systemic chemotherapy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progress free survival rate | 3 years | The rate of patient without progress disease in 3 years after treatment |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival rate | 3 years | The rate of patient alive in 3 years after treatment |
| Local area control rate. | 3 years | The rate of patient without recurrence in 3 years after treatment |
| No distant metastatic survival. | 3 years | The rate of patient without metastatic disease in 3 years after treatment |
| objective response rate | 3 years | the percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment. |
Countries
China
Contacts
Primary Contactjunguo bu, doctor
Backup Contactjiqiang li, doctor
Outcome results
None listed